Internuclear opthalmoplegia: Difference between revisions

(Text replacement - "* " to "*")
Line 2: Line 2:
[[File:Ino v2.png|thumbnail|Internuclear opthalmoplegia, courtesy of sketchy medicine]]
[[File:Ino v2.png|thumbnail|Internuclear opthalmoplegia, courtesy of sketchy medicine]]


*One and one-half syndrome
*Disruption of conjugate gaze.
*Affected eye has impaired adduction when looking contralateral (to affected eye)
*Results in [[diplopia]] when looking contralateral (to affected eye).
*Results in [[diplopia]] when looking contralateral (to affected eye)
*Localized to Midbrain or Pons.
*Usually results from a lesion in the brainstem
*Paramedian Pontine Reticular Formation (PPRF) is the conjugate gaze center for horizontal eye movements. Innervates ipsilateral Abducens (CN VI) nucleus. Abducens nucleus signals ipsilateral lateral rectus to contract and sends a second via MLF to contralateral oculomotor (CN III) nucleus, causing contraction on the contralateral medial rectus.
*Lesions in the Medial Longitudinal Fasiculus (MLF) result in intranuclear ophthalmoplegia (INO).
*Associated with one and one-half syndrome (lesion involving the PPRF and ipsilateral MLF)


==Clinical Features==
==Clinical Features==
 
*Weakness in adduction of affected eye with limitation in horizontal gaze.
*May result in horizontal diplopia
*Horizontal nystagmus in unaffected eye
*Convergence remains intact (differentiates CN III palsy from INO)


==Differential Diagnosis==
==Differential Diagnosis==
 
*Multiple Sclerosis (often presents with bilateral internuclear ophthalmoplegia)
*Cerebrovascular disease
*Malignancy located in brainstem and 4th ventricle
*CN III palsy


==Evaluation==
==Evaluation==
 
*Neurologic exam
*The use of optokinetic tape is highly sensitive for testing for INO
*MRI


==Management==
==Management==
 
*Symtoms will often resolve on their own. Patients with cerebrovascular disease are less likely to have recovery.
 
*Patching of eye can aid in relief of diplopia
==Disposition==
*Diframpadine, potassium channel blocker, has been used in patients with demyelinating disease
 
 
==See Also==
 


==References==
==References==
<references/>
<references/>
Ropper A, Klein J, Samuels M. Adams and Victor's Principles of Neurology 10th Edition. McGraw-Hill Education / Medical; 2014.
<references/>
Serra A, Skelly MM, Jacobs JB, et al. Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Neurology 2014; 83:192.


[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Symptoms]]
[[Category:Symptoms]]

Revision as of 05:09, 4 August 2017

Background

Internuclear opthalmoplegia, courtesy of sketchy medicine
  • Disruption of conjugate gaze.
  • Results in diplopia when looking contralateral (to affected eye).
  • Localized to Midbrain or Pons.
  • Paramedian Pontine Reticular Formation (PPRF) is the conjugate gaze center for horizontal eye movements. Innervates ipsilateral Abducens (CN VI) nucleus. Abducens nucleus signals ipsilateral lateral rectus to contract and sends a second via MLF to contralateral oculomotor (CN III) nucleus, causing contraction on the contralateral medial rectus.
  • Lesions in the Medial Longitudinal Fasiculus (MLF) result in intranuclear ophthalmoplegia (INO).
  • Associated with one and one-half syndrome (lesion involving the PPRF and ipsilateral MLF)

Clinical Features

  • Weakness in adduction of affected eye with limitation in horizontal gaze.
  • May result in horizontal diplopia
  • Horizontal nystagmus in unaffected eye
  • Convergence remains intact (differentiates CN III palsy from INO)

Differential Diagnosis

  • Multiple Sclerosis (often presents with bilateral internuclear ophthalmoplegia)
  • Cerebrovascular disease
  • Malignancy located in brainstem and 4th ventricle
  • CN III palsy

Evaluation

  • Neurologic exam
  • The use of optokinetic tape is highly sensitive for testing for INO
  • MRI

Management

  • Symtoms will often resolve on their own. Patients with cerebrovascular disease are less likely to have recovery.
  • Patching of eye can aid in relief of diplopia
  • Diframpadine, potassium channel blocker, has been used in patients with demyelinating disease

References

Ropper A, Klein J, Samuels M. Adams and Victor's Principles of Neurology 10th Edition. McGraw-Hill Education / Medical; 2014.

Serra A, Skelly MM, Jacobs JB, et al. Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Neurology 2014; 83:192.